Michael Tanen

4.3k total citations
21 papers, 2.2k citations indexed

About

Michael Tanen is a scholar working on Molecular Biology, Physiology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Michael Tanen has authored 21 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Physiology and 4 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Michael Tanen's work include Alzheimer's disease research and treatments (5 papers), Peroxisome Proliferator-Activated Receptors (4 papers) and Computational Drug Discovery Methods (3 papers). Michael Tanen is often cited by papers focused on Alzheimer's disease research and treatments (5 papers), Peroxisome Proliferator-Activated Receptors (4 papers) and Computational Drug Discovery Methods (3 papers). Michael Tanen collaborates with scholars based in United States, United Kingdom and South Africa. Michael Tanen's co-authors include Joel P. Berger, David E. Moller, Karen Snyder, Gary Herman, Arthur Bergman, Wesley Tanaka, Bingming Yi, John A. Wagner, Koen Vandyck and C. Melinda Stevens and has published in prestigious journals such as Journal of Biological Chemistry, Molecular and Cellular Biology and Brain Research.

In The Last Decade

Michael Tanen

21 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Tanen United States 14 972 886 659 436 319 21 2.2k
Anca D. Dobrian United States 27 806 0.8× 537 0.6× 690 1.0× 440 1.0× 362 1.1× 59 2.7k
Baichun Yang United States 25 853 0.9× 981 1.1× 605 0.9× 232 0.5× 366 1.1× 53 3.3k
Hiroyuki Odaka Japan 26 888 0.9× 822 0.9× 549 0.8× 302 0.7× 607 1.9× 45 2.3k
Nadeeja Wijesekara Canada 25 1.2k 1.2× 519 0.6× 853 1.3× 337 0.8× 912 2.9× 33 2.8k
James R. Paterniti United States 25 1.9k 2.0× 672 0.8× 716 1.1× 307 0.7× 658 2.1× 46 3.1k
Asger Lund Denmark 24 923 0.9× 1.8k 2.0× 455 0.7× 337 0.8× 1.1k 3.5× 79 2.6k
Nobuo Sakamoto Japan 25 649 0.7× 502 0.6× 709 1.1× 259 0.6× 481 1.5× 153 2.9k
Michael Mark Germany 26 1.2k 1.3× 2.1k 2.4× 375 0.6× 304 0.7× 1.2k 3.8× 52 3.1k
Ji Hee Lim South Korea 28 901 0.9× 349 0.4× 497 0.8× 473 1.1× 294 0.9× 46 2.2k
Philippe Poulain France 16 1.4k 1.4× 528 0.6× 644 1.0× 424 1.0× 818 2.6× 34 2.3k

Countries citing papers authored by Michael Tanen

Since Specialization
Citations

This map shows the geographic impact of Michael Tanen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Tanen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Tanen more than expected).

Fields of papers citing papers by Michael Tanen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Tanen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Tanen. The network helps show where Michael Tanen may publish in the future.

Co-authorship network of co-authors of Michael Tanen

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Tanen. A scholar is included among the top collaborators of Michael Tanen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Tanen. Michael Tanen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lane, Brian R., Kateřina Vlasáková, Sabrina L. Noyes, et al.. (2018). Evaluation of Urinary Renal Biomarkers for Early Prediction of Acute Kidney Injury Following Partial Nephrectomy: A Feasibility Study. European Urology Focus. 6(6). 1240–1247. 13 indexed citations
2.
Dockendorf, Marissa F., John Palcza, Jack Tseng, et al.. (2018). Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK‐8931) in Healthy Japanese Adults: A Randomized, Placebo‐Controlled Study. Clinical Pharmacology & Therapeutics. 105(5). 1234–1243. 18 indexed citations
3.
Seeburger, Jeffrey L., Daniel Holder, Marc Combrinck, et al.. (2015). Cerebrospinal Fluid Biomarkers Distinguish Postmortem-Confirmed Alzheimer's Disease from Other Dementias and Healthy Controls in the OPTIMA Cohort. Journal of Alzheimer s Disease. 44(2). 525–539. 62 indexed citations
4.
Zuiker, Rob, Marcella Ruddy, Robin Mogg, et al.. (2015). Kinetics of TH2 biomarkers in sputum of asthmatics following inhaled allergen. European Clinical Respiratory Journal. 2(1). 28319–28319. 10 indexed citations
5.
Fraser, Stephanie, et al.. (2014). Next Generation Ligand Binding Assays—Review of Emerging Real-Time Measurement Technologies. The AAPS Journal. 16(5). 914–924. 4 indexed citations
6.
McAvoy, Thomas, Michael E. Lassman, Daniel S. Spellman, et al.. (2014). Quantification of Tau in Cerebrospinal Fluid by Immunoaffinity Enrichment and Tandem Mass Spectrometry. Clinical Chemistry. 60(4). 683–689. 59 indexed citations
7.
Stone, Julie A., Huub Jan Kleijn, Marissa F. Dockendorf, et al.. (2013). O4–05–05: Consistency of BACE inhibitor‐mediated brain amyloid production inhibition by MK‐8931 in Alzheimer's disease patients and healthy young adults. Alzheimer s & Dementia. 9(4S_Part_17). 6 indexed citations
8.
Forman, Mark S., John Palcza, Jack Tseng, et al.. (2012). P4‐196: The novel BACE inhibitor MK‐8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single‐ and multiple‐dose administration. Alzheimer s & Dementia. 8(4S_Part_19). 38 indexed citations
9.
Forman, Mark S., Marissa F. Dockendorf, John Palcza, et al.. (2012). P1‐225: A study to evaluate the pharmacokinetics and pharmacodynamics of single and multiple oral doses of the novel BACE inhibitor MK‐8931 in Japanese subjects. Alzheimer s & Dementia. 8(4S_Part_5). 3 indexed citations
10.
11.
Herman, Gary, Arthur Bergman, Fang Liu, et al.. (2006). Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects. The Journal of Clinical Pharmacology. 46(8). 876–886. 146 indexed citations
12.
13.
Herman, Gary, C. Melinda Stevens, Koen Vandyck, et al.. (2005). Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clinical Pharmacology & Therapeutics. 78(6). 675–688. 414 indexed citations
14.
Berger, Joel P., Ann Petro, Karen L. MacNaul, et al.. (2003). Distinct Properties and Advantages of a Novel Peroxisome Proliferator-Activated Protein γ Selective Modulator. Molecular Endocrinology. 17(4). 662–676. 271 indexed citations
15.
Woods, John, Michael Tanen, David J. Figueroa, et al.. (2003). Localization of PPARδ in murine central nervous system: expression in oligodendrocytes and neurons. Brain Research. 975(1-2). 10–21. 96 indexed citations
16.
Combs, Terry P., John A. Wagner, Joel P. Berger, et al.. (2002). Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization. Endocrinology. 143(3). 998–1007. 497 indexed citations
17.
Berger, Joel P., Michael Tanen, Alex Elbrecht, et al.. (2001). Peroxisome Proliferator-activated Receptor-γ Ligands Inhibit Adipocyte 11β-Hydroxysteroid Dehydrogenase Type 1 Expression and Activity. Journal of Biological Chemistry. 276(16). 12629–12635. 175 indexed citations
18.
Jeyakumar, M., Michael Tanen, & Milan K. Bagchi. (1997). Analysis of the Functional Role of Steroid Receptor Coactivator-1 in Ligand-Induced Transactivation by Thyroid Hormone Receptor. Molecular Endocrinology. 11(6). 755–767. 38 indexed citations
19.
20.
Tong, Guo‐Xia, Michael Tanen, & Milan K. Bagchi. (1995). Ligand Modulates the Interaction of Thyroid Hormone Receptor β with the Basal Transcription Machinery. Journal of Biological Chemistry. 270(18). 10601–10611. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anca D. Dobrian Breakdown of academic impact, for papers by Baichun Yang Breakdown of academic impact, for papers by Hiroyuki Odaka Breakdown of academic impact, for papers by Nadeeja Wijesekara Breakdown of academic impact, for papers by James R. Paterniti Breakdown of academic impact, for papers by Asger Lund Breakdown of academic impact, for papers by Nobuo Sakamoto Breakdown of academic impact, for papers by Michael Mark Breakdown of academic impact, for papers by Ji Hee Lim Breakdown of academic impact, for papers by Philippe Poulain
Rankless by CCL
2026